Ruboxistaurin (RBX) May Reduce Risk of Vision Loss in Diabetics

A multicenter international study chaired by a Joslin Diabetes Center investigator and reported in the July issue of the American Diabetes Association’s journal Diabetes brings hopeful news to the 18 million people in the United States — and millions more worldwide — with type 1 or type 2 diabetes. Initial results of the Phase III clinical trial demonstrated that 32 milligrams per day of ruboxistaurin (RBX) was well tolerated and may reduce the risk of moderate vision loss, especially in patients with diabetic macular edema.

Full article (259 words) »

The story of a noble man and his noble Mother

HYDERABAD: Kolavennu Venkatesh, the young chess player who fought a bitter legal battle to end his life before a debilitating muscular degeneration killed him, ended his struggle quietly at dawn on Friday. The death came two days after the Andhra Pradesh HC rejected his plea for euthanasia, a move the patient's mother said would have enabled him to donate his organs before muscular dystrophy rendered them useless.

Full article (553 words) »
Protected by Comment Guard Pro